VIITAL Trademark

Trademark Overview

On Wednesday, June 19, 2019, a trademark application was filed for VIITAL with the United States Patent and Trademark Office. The USPTO has given the VIITAL trademark a serial number of 88479903. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 21, 2022. This trademark is owned by Abeona Therapeutics, Inc.. The VIITAL trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Providing information on the efficacy of a gene therapy preparation for the treatment of recessive dystrophic epidermolysis bullosa
viital

General Information

Serial Number88479903
Word MarkVIITAL
Filing DateWednesday, June 19, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 21, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, August 20, 2019

Trademark Statements

Description of MarkThe mark consists of the word "VIITAL" with the "VII" in green and the "TAL" in blue.
Indication of Colors claimedThe color(s) green and blue is/are claimed as a feature of the mark.
Goods and ServicesProviding information on the efficacy of a gene therapy preparation for the treatment of recessive dystrophic epidermolysis bullosa

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, June 29, 2019
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAbeona Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10019
Party NameAbeona Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10019

Trademark Events

Event DateEvent Description
Monday, November 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 21, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, April 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 21, 2022SOU EXTENSION 5 GRANTED
Monday, April 4, 2022SOU EXTENSION 5 FILED
Monday, April 4, 2022TEAS EXTENSION RECEIVED
Wednesday, September 29, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 27, 2021SOU EXTENSION 4 GRANTED
Monday, September 27, 2021SOU EXTENSION 4 FILED
Monday, September 27, 2021TEAS EXTENSION RECEIVED
Wednesday, April 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 12, 2021SOU EXTENSION 3 GRANTED
Monday, April 12, 2021SOU EXTENSION 3 FILED
Monday, April 12, 2021TEAS EXTENSION RECEIVED
Wednesday, October 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 12, 2020SOU EXTENSION 2 GRANTED
Monday, October 12, 2020SOU EXTENSION 2 FILED
Monday, October 12, 2020TEAS EXTENSION RECEIVED
Wednesday, April 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 6, 2020SOU EXTENSION 1 GRANTED
Monday, April 6, 2020SOU EXTENSION 1 FILED
Monday, April 6, 2020TEAS EXTENSION RECEIVED
Tuesday, March 17, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 17, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 13, 2020TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, October 15, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 20, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 20, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 31, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 16, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 15, 2019ASSIGNED TO EXAMINER
Saturday, June 29, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, June 22, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

viital recessive dystrophic epidermolysis bullosa treatment preparation information efficacy gene therapy